The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Advances in Hematology"
DOI: 10.1177/20406207221112899
Abstract: Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disorder clinically defined by cytopenias, bone marrow failure, and an increased risk of progressing to acute myeloid leukemia (AML). Traditionally, first-line treatment for patients with higher-risk… read more here.
Keywords: mds; pevonedistat; myeloid leukemia; syndrome mds ... See more keywords
Incidence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients (pts) with a germline (g) BRCA mutation (m) and platinum-sensitive relapsed ovarian cancer (PSR OC) receiving maintenance olaparib in SOLO2: Impact of prior lines of platinum therapy.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.5548
Abstract: 5548Background: Olaparib has been investigated and subsequently approved as maintenance treatment after response to platinum-based chemotherapy in pts with relapsed OC. A relationship between incre... read more here.
Keywords: syndrome mds; platinum; maintenance; myelodysplastic syndrome ... See more keywords